3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Neoplasms
10
Carcinoma, Renal Cell
9
Ovarian Neoplasms
7
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Lymphoma
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Kidney Diseases
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Interventions
Sunitinib
3
avelumab
2
Nutrition Assessment
2
Axitinib
2
spartalizumab
1
pembrolizumab
1
etelcalcetide hydrochloride
1
aldesleukin
1
Sorafenib
1
Resistance Training
1
Plasma Exchange
1
Interleukin-2
1
Adalimumab
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Kidney Diseases
×
avelumab
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts